- Home
- CHRS vs FT Comparison
CHRS vs FT Comparison
Compare CHRS & FT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- FT
- Stock Information
- Founded
- CHRS 2010
- FT 1988
- Country
- CHRS United States
- FT United States
- Employees
- CHRS N/A
- FT N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- FT Trusts Except Educational Religious and Charitable
- Sector
- CHRS Health Care
- FT Finance
- Exchange
- CHRS Nasdaq
- FT Nasdaq
- Market Cap
- CHRS 191.3M
- FT 185.7M
- IPO Year
- CHRS 2014
- FT N/A
- Fundamental
- Price
- CHRS $1.39
- FT $7.56
- Analyst Decision
- CHRS Strong Buy
- FT
- Analyst Count
- CHRS 4
- FT 0
- Target Price
- CHRS $5.38
- FT N/A
- AVG Volume (30 Days)
- CHRS 2.0M
- FT 63.0K
- Earning Date
- CHRS 03-12-2025
- FT 01-01-0001
- Dividend Yield
- CHRS N/A
- FT 7.85%
- EPS Growth
- CHRS N/A
- FT N/A
- EPS
- CHRS N/A
- FT N/A
- Revenue
- CHRS $304,340,000.00
- FT N/A
- Revenue This Year
- CHRS $2.47
- FT N/A
- Revenue Next Year
- CHRS N/A
- FT N/A
- P/E Ratio
- CHRS N/A
- FT N/A
- Revenue Growth
- CHRS 44.19
- FT N/A
- 52 Week Low
- CHRS $0.66
- FT $5.97
- 52 Week High
- CHRS $2.97
- FT $7.23
- Technical
- Relative Strength Index (RSI)
- CHRS 45.86
- FT 62.53
- Support Level
- CHRS $1.38
- FT $7.19
- Resistance Level
- CHRS $1.60
- FT $7.35
- Average True Range (ATR)
- CHRS 0.13
- FT 0.09
- MACD
- CHRS -0.03
- FT 0.03
- Stochastic Oscillator
- CHRS 9.52
- FT 80.43
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About FT Franklin Universal Trust
Franklin Universal Trust is a closed-end management investment company. Its primary investment objective is to provide high, current income consistent with the preservation of capital. Its secondary objective is the growth of income through dividend increases and capital appreciation. The fund invests in two asset classes being the high yield bonds and utility stocks.